Bedrijf laden
Keep exploring
The themes Beone Medicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
EXELExelixis, Inc.US$ 17BA+
JAZZJazz Pharmaceuticals plcUS$ 15,4BA
HALOHalozyme Therapeutics, Inc.US$ 11,5BA+
TECHBIO-Techne CorpUS$ 11,4BA+
TGTXTG Therapeutics, Inc.US$ 9,8BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 okt 2026BAGraded B, now A
Hoe het geld verdient
- Sales of cancer medicines98%
De omzetaandelen zijn schattingen voor Q1 2026, geen cijfers uit een ingediend rapport.
Concurreert met
Wat het verkoopt6
BRUKINSA (zanubrutinib)
A pill for several blood cancers that blocks Bruton tyrosine kinase, a protein that helps certain cancer cells grow.
TEVIMBRA (tislelizumab)
An antibody treatment that blocks a signal cancer cells use to reduce the immune system's attack on them.
BEQALZI (sonrotoclax)
A pill that blocks the B-cell lymphoma 2 protein, which can help cancer cells survive; it is approved in the United States for certain mantle cell lymphoma patients.
Nog 3 tonen
XGEVA (denosumab)
An antibody medicine marketed by BeOne in China to help prevent bone complications in people with cancer and to treat giant cell tumor of bone.
BLINCYTO (blinatumomab)
A medicine marketed by BeOne in China for acute lymphoblastic leukemia that helps immune cells recognize and attack cancer cells.
KYPROLIS (carfilzomib)
A medicine marketed by BeOne in China for multiple myeloma that interferes with a process cancer cells use to dispose of unwanted proteins.
Wie het koopt2
- Commercial distributors and other medicine buyers purchase BeOne's products for sale or supply to treatment providers.
- Government health systems and private insurers decide which medicines they cover and reimburse; patients receive the medicines through their cancer care.
Waar het op steunt, en wat het kan breken
Waar het bedrijf van afhangt
- 1A large share of sales comes from BRUKINSA, so its continued use by doctors and patients and its coverage by health systems and insurers matter to revenue.
- 2Sales depend on government and private reimbursement, including coverage decisions and negotiated medicine prices in China and other markets.
- 3For licensed medicines such as XGEVA, BLINCYTO and KYPROLIS, BeOne depends on partner agreements and partner or contract manufacturers for supply.
- 4BeOne relies on some outside manufacturers, suppliers and research contractors for medicines, materials and development work.
Wat er mis kan gaan
- 1Clinical trials may not show that medicines work or are safe enough for regulators to approve them; delays, trial failures or safety problems could prevent new medicines or uses from reaching patients.
- 2Competition from medicines such as IMBRUVICA, CALQUENCE and KEYTRUDA, along with changes in coverage, reimbursement or medicine pricing, could reduce sales or patient access.
- 3BeOne operates across China, the United States and other markets, so changes in government policy, regulation or trade relations can affect approvals, manufacturing, sales and the movement of money.
Over Beone Medicines Ltd.
BeOne Medicines discovers, develops, makes and sells treatments for cancer. Its main medicine, BRUKINSA (zanubrutinib), is a pill that blocks Bruton tyrosine kinase, a protein involved in some blood cancers. It also sells TEVIMBRA, an antibody that blocks a signal cancers use to dampen immune attacks, and markets licensed cancer medicines in China.
- Hoofdkantoor
- Basel, Switzerland
- Opgericht in
- 2010
- Medewerkers
- More than 12,000 (Q2 2026, medium)
- Genoteerd aan
- Nasdaq
- Einde boekjaar
- December 31
Gebouwd uit de eigen deponeringen van Beone Medicines Ltd. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
